But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

CRISPR screens often mislead cancer research because bacterial Cas9 components trigger immune reactions in mice. ETH Zurich ...